Hodinový prehľad - Zdravotnícke a vedecké zaujímavosti

Súhrn: Inside the SPOT Trial Researchers invited roughly 226,000 insured adults to participate The trial was funded by SkinVision, the app's maker; the researchers reported no other financial ties Patients are bringing up skin cancer apps more often.

Súhrn: TOPLINE Patients with relapsed/refractory large B-cell lymphoma (LBCL) who achieved optimal fludarabine exposure during lymphodepletion chemotherapy had better progression-free survival after chimeric antigen receptor (CAR) T-cell therapy than those who did not achieve optimal exposure METHODOLOGY - Researchers conducted a prospective cohort study to assess whether fludarabine exposure during lymphodepletion chemotherapy was associated with CAR T-cell therapy outcomes in patients with LBCL - The final analysis included 54 patients with relapsed/refractory LBCL at a Spanish hospital between March 2021 and September 2022.